⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025

Supplementary Figure S4 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer

Tony Georgiev Sara Puglioli Lucrezia Principi Ettore Gilardoni Christian Pellegrino Gabriele Bassi Andrea Galbiati Dario Neri Samuele Cazzamalli

View at Publisher

Ask AI

Bookmark

Share

Key Points

Promising results indicate the potential of psma-targeted small molecule-drug conjugates in treating prostate cancer, enhancing targeted therapy.
The lc chromatogram of I4 demonstrates peak patterns that suggest effective compound separation and identification relevant to drug application.
Developing drugs based on a postprolyl peptidase-cleavable linker could improve therapeutic efficacy in prostate cancer management.
This research highlights the importance of linker design in enhancing the specificity and effectiveness of cancer-targeted therapies.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Novel small molecule-drug conjugates show potential in treating prostate cancer, suggesting effective targeting via a peptidase-cleavable linker.

Abstract

LC chromatogram of I4

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Georgiev et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a219f8 https://doi.org/10.1158/1535-7163.30255227

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
2Supplementary Figure S2 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
3Supplementary Figure S5 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
4Supplementary Figure S3 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
5Supplementary Figure S6 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025

More related papers

Supplementary Figure S8 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
Supplementary FIgure S7 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
Supplementary Figure S12 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025